The SOMAscan® Platform
The SOMAscan® platform is being applied to wide range of diseases and conditions to deliver insights that enable biomarker discovery, diagnostics development, and pharmaceutical discovery and development, and health management.
Measuring Biology in Real-Time
SomaLogic is working with leading academic institutions and biobanks around the world to assemble the world’s largest database of protein measurements, applying our SOMAscan® assay to thousands of samples with extensive clinical outcome data.
We are using state-of-the-art machine learning and bioinformatics capabilities to transform this massive collection of data into quantitative risk assessments and reliable physiological and lifestyle insights.
The SOMAscan® Assay: An Unprecedented Protein Biomarker Discovery and Development Tool
Protein measurements provide a real-time picture of what is happening in our bodies at any given time. They are the best indicators of when things are normal and when things are starting to going awry.
Understanding the many protein changes that underlie both health and disease requires a new kind of proteomic technology that can measure both broadly (thousands of proteins simultaneously) and deeply (high- and low-abundance proteins). Only the SOMAscan assay provides this expansive view.
In essence, the SOMAscan assay converts a difficult problem (protein measurement) into a straightforward solution (DNA measurement). This surprising trick relies on the distinctive properties of the proprietary protein binding reagents used in the assay.
SOMAmer® Reagents: A New Class of Protein-Affinity Molecules
SOMAmer (Slow Off-rate Modified Aptamer) reagents consist of a short single-stranded DNA sequence that incorporates a series of modifications that give the SOMAmer “protein-like” appendages. These chemical modifications in turn allow the SOMAmer to tightly bind its target protein in ways never before possible. The specificity is critical for measuring each protein in highly complex protein mixtures such as blood.
For more information, please see: Rohloff, JC et al. (2014) “Nucleic acid ligands with protein-like side chains: Modified aptamers and their use as diagnostic and therapeutic agents.” Molecular Therapy Nucleic Acids 3(10):e201.